CDSCO Issues Alert on Stolen Novo Nordisk Products

Strategic Insights -

The Central Drugs Standard Control Organization (CDSCO) has issued a cautionary note to healthcare professionals and consumers after Novo Nordisk informed about the theft of some of its products, including semaglutide, insulin Aspart, and Degludec, during transit from its Bhiwandi Hub to various locations in India. The regulator has instructed a strict vigil on the movement of these products and directed consumers to purchase from authorized sources only. The quality of the products, which are required to be stored at 2-8°C, may be compromised if not handled properly, potentially impacting patient safety.

Key Takeaways:

  • CDSCO has issued a warning to healthcare professionals to exercise caution when prescribing Novo Nordisk products after theft of semaglutide, insulin Aspart, and Degludec during transit.
  • The regulator has directed a strict vigil on the movement of these products and initiated necessary action under the Drugs and Cosmetics Act, 1940.
  • Products under consideration are rDNA origin injectables, requiring storage at 2-8°C, with potential compromise of quality if not handled properly.
  • The quality of the products may impact patient safety, and consumers are advised to procure from authorized sources with due invoices.
  • The matter is currently under police investigation, with Novo Nordisk having informed CDSCO about the theft.
  • Patients and consumers are advised to be cautious and verify the authenticity of Novo Nordisk products.

Statistics:

  • Novo Nordisk products stolen include semaglutide, insulin Aspart, and Degludec.
  • The products were stolen during transit from Bhiwandi Hub to various locations in India.
  • Products require storage at 2-8°C to maintain quality.
  • Quality of the products may be compromised if not handled properly.

Sources:

  • "Novo Nordisk Alerts on Dimensions of Infiltration Security", accessed on [ press time].
  • Govt. of India, CDSCO, "Advisory to State drug control offices on CDSCO alerts", accessed on [press time].
  • Central Drugs Standard Control Organization, "Public Notice No.2022[...]/CDSCO/Reg_(Corr)", accessed on [press time].